DELRAY BEACH, Fla., June 22, 2015 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today that it has now successfully tested 12 different assays on its Firefly Dx breadboard prototype PCR (polymerase chain reaction) pathogen detection system. Using both its own as well as third-party assays, Firefly Dx successfully detected all the pathogens it tested for in less than 20 minutes.
All tests were performed on the Firefly Dx breadboard, which is significantly faster than standard laboratory equipment and protocols. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. In addition, there is significantly less chance of sample contamination compared to existing testing methods.
PositiveID’s Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment, highly trained personnel, and can take hours or even days to provide results. Firefly’s applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
“We are very pleased with our progress with the testing and optimization of Firefly Dx, and are confident that with continued development success, we will be able to deliver a real-time PCR system that can revolutionize point-of-need biological detection from an ease of use, time and cost perspective,” stated William J. Caragol, Chairman and CEO of PositiveID.
Sourced through Scoop.it from: www.nasdaq.com